

Supplementary data

Supplementary Table 1 Mean differences (\pm SD) between the luseogliflozin and placebo groups in secondary endpoints at week 12.

Comparison vs Placebo	Luseogliflozin 2.5 mg (n=80)	Luseogliflozin 5 mg (n=86)	Luseogliflozin 10 mg (n=79)
FPG (mmol/L)	-0.38 (95% CI: -0.86; 0.11) NS	-0.63 (95% CI: -1.09; -0.15) p=0.022	-0.66 (95% CI: -1.15; -0.18) p=0.022
PPG (mmol/L)	-1.22 (95% CI: -2.14; -0.3) p=0.019	-0.73 (95% CI: -1.62; 0.15) NS	-1.48 (95% CI: -2.38; -0.57) p=0.005
Body weight (kg)	-0.87 (95% CI: -1.64; -0.09) p=0.029	-1.02 (95% CI: -1.76; -0.27) p=0.015	-1.51 (95% CI: -2.28; -0.75) p<0.001
Waist circumference (cm)	-0.34 (95% CI: -1.72; 1.04) NS	-0.72 (95% CI: -2.04; 0.60) NS	-1.03 (95% CI: -2.38; 0.33) NS

FPG, fasting plasma glucose; PPG, postprandial plasma glucose; NS, non significant.

Supplementary Figure 1 Proportions of subjects reaching pre-defined HbA1c levels at W12 .

